NewAmsterdam Pharma Company NV - Warrants (15/11/2027) Return on Equity

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) posts a ROE of -41.1%. That is below the sector sector average of -5.87%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For its sector stocks, a ROE near -5.87% is typical. NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s -41.1% is lower that level. That is roughly 600.3% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -41.1%; use YoY and peer views to separate noise from signal.

Context for NAMSW's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -5.87%), and (3) consistency with growth and profitability. This page covers the first two; NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s other metric pages and overview cover the third.